Clinical Trial Search

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline

Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale

Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg

Primary: Number of Participants Who Had a Prostate-specific Antigen (PSA) Response — 52 Participants

Primary: Proportion of Patients With PSA Response — 0.33; 0.24; 0.18 Proportion of participants

Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants

Primary: Clinical Benefit Rate From Cabozantinib (XL184) — 10 Participants

Primary: Undetectable PSA Rate — 42; 34 participants — p=0.16

Primary: Maximum Tolerated Dosage (MTD) of Cabazitaxel-carboplatin in the Phase I Portion of Study — 25 mg/m^2

Primary: Overall Response Rate (ORR) — 50 percentage of participants

Primary: Proportion of Patients With PSA Decline by 50% From Baseline — 9; 5 Participants

Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients

Primary: Metabolic Syndrome — 0; 0 kilograms

Primary: Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) — 6.8 percentage of participants

Primary: Mean Prostate Specific Antigen (PSA) Level — 0.61; 0.70; 0.54 ng/mL

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 Given Every Two Weeks. — 20 mg/kg every 2 weeks

Primary: Efficacy as Assessed by 3-year Prostate-specific Antigen Progression-free Survival Rate — 22; 3 Participants

Primary: Progression-free Survival (PFS) Based on the RECIST Criteria — 5.5; 3.7 months — p=0.02

Primary: Progression Free Survival (PFS) — 2.8; 9.0; 11.5; 10.1 Months — p=0.44

Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants

Primary: Percent Probability of Participants With 6-month Progression-free Survival (PFS) — 43.9 percent probability

Primary: Progression-free Survival (PFS) — 1 Participants

Primary: Overall Survival — 91.6 weeks

Primary: Progression Free Survival — 16.1 months

Primary: Composite Time to Disease Progression (cTTP) for Participants Treated With Cixutumumab — 4.9; 3.2 months

Primary: Percentage of Participants With PSA50 Response — 2 Participants

Primary: Gallium Ga 68-DOTATATE Uptake — 11; 4; 1 Participants